4D Molecular Therapeutics FDMT Q1 2026 Earnings NarrowerthanExpected Loss Lifts Shares Protara Therapeutics TARA Q1 2026 Earnings Narrower Loss Beats Street Estimates on Cost Management BNR Q3 2022 Earnings Narrower Loss Surprises as Revenue Remains Undisclosed WAVE Q1 2026 Earnings Strong EPS Beat Amid No Revenue Stock Declines Eikon Therapeutics Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline KPRX Q1 2026 Earnings NarrowerThanExpected Loss Drives Optimism Despite Revenue Gap